Background: Differential diagnosis of systemic inflammatory response syndrome (SIRS) with or without infectious cause is critically important in terms of initiating antimicrobial agents in case of infectious etiology such as ventilator-associated pneumonia (VAP). The aim of this study was to determine the diagnostic and prognostic roles of C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α) in differentiating between ventilator-associated pneumonia and SIRS without infectious etiology.
INTRODUCTION
Biomarker measurement in critically ill patients has received increasing attention (1, 2) . Biomarkers can aid in diagnosis or prognosis (1) To address these issues, we chose to study a common yet challenging problem in the ICU -the diagnosis of VAP.
VAP is a very common cause of morbidity and mortality in ICU patients (2, 6, 7) . The clinical diagnosis of VAP is usually based on systemic signs of infection, new or expanding pulmonary infiltrates seen on chest roentgenogram and bacteriologic evidence of pulmonary parenchymal infection (6) . Although, microbiologic diagnosis of VAP is crucial for specific diagnosis and management, it takes a substantial period of time to obtain culture results.
Thus, VAP is an important ICU problem that would greatly benefit from enhanced diagnostic capacity provided by rapid biomarker measurements (8) (9) (10) .
CRP measurement helps the diagnosis of infection (11).
However, specificity for infection has been raised as a limitation (12) . CRP is an acute-phase protein produced by the liver, the levels of which rise in response to inflammation. CRP concentrations below ~10 mg/L are considered normal. CRP increases slightly with age, pregnancy, various kinds of mild inflammation and viral infections (10-40 mg/L). Higher levels are observed in severe bacterial infections. In contrast to CRP, TNF-α is an early indicator of inflammation (13) arising from both infectious and non-infectious causes. TNF-α plays an important role in pathophysiology of many inflammatory disorders, whether due to infection or due to non-infectious causes (12, (14) (15) (16) .
We therefore interrogated the diagnostic and prognostic value of both CRP and TNF-α in enhancing the clinical distinction between 1) critically ill patients with and without a clinically defined SIRS, and 2) with and without infection (17) (18) (19) . To address these issues, we chose to follow a prospective cohort of critically ill patients for the development of VAP. From a diagnostic perspective, we reasoned that TNF-α should distinguish between patients with SIRS and without SIRS (non-SIRS)
while CRP should perform best at distinguishing infection (VAP) from no infection (non-VAP). We compared the diagnostic ability of these two prototype biomarkers to simple clinical scores. Finally, we separately tested the prognostic value of these measurements, again compared to prognosis from simple clinical scores. These prospective and carefully timed measurements raise doubt as to whether current biomarkers add substantially to current clinical practice in VAP diagnosis and prognosis. breaths/min or PaCO2 ≤32 mmHg, and 4) white blood cell count ≥12,000 or ≤4,000/mL, or presence of more than 10%
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immature neutrophils (20, 21) . VAP was defined by the presence of mechanical ventilation, SIRS, a CPIS of greater than or equal to 6 and, subsequently, a positive endotracheal aspirate culture (6) . Endotracheal aspirate cultures were only performed in patients who had a
CPIS6 (22).
Patients were then categorized into the following three developed VAP, the day of VAP development was defined as the first study day. Data were collected in the first, third and seventh study days. These data comprised the following items: Temperature, heart rate, respiratory rate, blood pressure, laboratory analysis including white blood cell count (WBC), percentage of neutrophils and band forms, serum creatinine, arterial blood gas analysis, and plasma CRP and TNF-α concentrations. In addition, CPIS and APACHE II scores were determined (23) .
CRP and TNF-α measurements
Blood samples were drawn on the first, third and seventh study days for CRP and TNF-α measurements.
Blood samples were collected in glass tubes and placed in ice containers. Samples were processed within two hours by centrifuging at 1,600 g for 15 minutes. Plasma supernatant was rapidly frozen and preserved at -70 o C until final analysis. CRP concentration was measured using a particle enhanced turbidimetris assay (Roche, Germany)
and TNF-α concentration was measured using an enzymelinked immune sorbent assay (ELISA. eBioscience, Austria).
Statistical analysis
We used the Shapiro-Wilk test to determine whether data were normally distributed. Table 1 .
Biomarkers as diagnostic factors
There were no significant differences in the values of CRP and TNF-α between groups (between-subject differences or group effect) (Figure 1 ). In addition, there was no statistically significant time trend (within-subject differences or time effect) for CRP and TNF-α ( Figure 1 ).
Considering both time effect and group effect, the changes were not significantly different for CRP (P= 0.86) and TNF-α (P=0.69). Thus, TNF-α was not effective in diagnosing SIRS, and CRP was not effective in diagnosing VAP in patients who had SIRS.
We used ROC analysis to calculate the sensitivity and specificity of CRP to differentiate SIRS-non-VAP from SIRS-VAP and similar analysis for TNF-α. Table 2 and Figure 2 show the optimal cut-offs and corresponding sensitivities, specificities and area under the curve for CRP and TNF-α. At days 1, 3 and 7, TNF-α had sensitivity values >0.7, but the CRP at all times reached sensitivity <0.7. Considering the specificity, just CRP level at day 1 showed specificity >0.7. The area under the curve of both CRP and TNF-α on each given days was not significantly different from 0.5.
In contrast to these biomarkers, we found that every patient who had CPIS  6 had positive endotracheal aspirate cultures and, hence, VAP. Thus, in this setting CPIS  6 had 100% specificity. 
Biomarkers as prognostic factors
Two, eight and 17 patients died by days three, seven and 28 after ICU admission, respectively. We tested early biomarker levels (day 1 and day 3) for prognostic value of mortality, reasoning that many deaths had occurred by day 7 and day 7 was late in the typical course of VAP.
Biomarker levels (median and range) in survivors and nonsurvivors (28 days after study inclusion) on day one and day three are shown in Table 3 . While CRP and TNF-α
were not predictive of mortality, APACHE II scores were significantly different between survivors and nonsurvivors on day one (P=0.008) and day three (P=0.005). With regard to prognosis we found that clinical scoring using the APACHE II score was a highly significant predictor of 28-day mortality. In contrast, neither CRP nor TNF-α were predictive of 28-day mortality. In further analysis, we found that no change or reduction in concentration of TNF-α from day 1 to day 3 was more common in survivors than non-survivors. Hillas et al, also
demonstrated that higher level of CRP at day 7 in VAP patients was associated with development of septic shock, although it could not predict VAP survival (24) .
The sensitivity of CRP on day 1 to discriminate "SIRSnon-VAP" from "SIRS-VAP" was very low (e.g., 33.3%). In most previous studies, CRP levels have been referred to be an indicator of morbidity and mortality rather than a diagnostic test (10, 11, 17, 25, 26) . Póvoa et al. found that in community acquired sepsis patients admitted to the ICU, the survivors had a lower CRP level on days three to five of stay in the ICU compared to non-survivors (11) . The pattern of CRP changes could predict the postoperative complications and higher one-year mortality in patients undergoing esophagectomy (10) . CRP levels more than 10 mg/dL were associated with 6.6 times higher mortality in respiratory ICU patients (25) . Considering the prognostic utility of CRP, it was used successfully for assessing response to antibiotics (8) , risk stratification of cardiovascular disease (17) and for predicting acute brain dysfunction in critically-ill patients (26) .
In cardiac surgery patients, serum CRP was not a diagnostic marker for VAP although procalcitonin was (27) . Similar results of preference of procalcitonin over CRP was reported in discriminating SIRS and sepsis (18) and also as a marker for detection of early VAP (9) or VAP in patients with a successful cardiopulmonary resuscitation (28) . The assay of CRP in bronchoalveolar lavage fluid was also not helpful in the diagnosis of VAP (29) . Decrease in CRP, as decrease in PCT, Sequential Organ Failure Assessment and APACHE II was associated with the prediction of survival of VAP patients (30) . APACHE II is an established and feasible outcome predictor tool in critically-ill patients including septic patients who are at high risk of death and who are more likely to benefit from intervention (31, 32) . We found that APACHE II is a better predictor of survival compared to CRP and TNF-α.
In our study, TNF-α, similar to CRP, could not differentiate between "SIRS-VAP" and "SIRS-non-VAP", although higher TNF-α on day three was associated with a higher mortality. The sensitivity of TNF-α at all three time points was more than 70%, but the area under the curves of sensitivity and specificity was not significantly different from 0.5. In most studies, the trend of inflammatory mediators was compared between SIRS and sepsis/septic shock (19, 33) . A higher level of TNF-α was observed in sepsis patients compared to SIRS or control groups. Also, higher TNF-α level was associated with higher occurrence of disseminated intravascular coagulation and mortality. In contrast, it was reported that TNF-α dynamics were not associated with risk estimation of mortality in SIRS of infectious origin (19) . In our study, we found a prognostic role for TNF-α at D3, as higher level was inversely associated with survival, irrespective of the primary cause of inflammation.
Recently, simultaneous use of several inflammatory markers including cell-surface (e.g., triggering receptor expressed by myeloid cells-1, CD11b and CD62L) and soluble markers (IL-1beta, IL-6, IL-8, sTREM-1, Procalcitonin) has been used successfully to discriminate between VAP and non-VAP cases (34) . One limitation of our study was that we did not measure some other biomarkers such as IL-6 and IL-8 in our study.
The overall conclusion of the study is that TNF-α and CRP levels were not capable of differentiating "SIRS-non-VAP" from "SIRS-VAP" patients. Instead, a readily available diagnostic scoring system, CPIS  6, had 100% specificity for diagnosing VAP. Similarly, TNF-α and CRP levels had little prognostic ability while a standard clinical severity of illness scoring system, APACHE II, was significantly prognostic. These prospective and carefully timed measurements raise doubt as to whether current biomarkers add substantially to current clinical practice in VAP diagnosis and prognosis.
